Information & advocacy — not medical advice. We don't sell the drug; we help you afford it. Figures current as of June 2026.
The Medicare GLP-1 Bridge, explained
A temporary federal demonstration (the "Medicare GLP-1 Bridge", July 1, 2026 – December 31, 2027) that, for the first time, gives eligible Medicare Part D members access to certain GLP-1s for weight loss — at a flat $50/mo copay. CMS runs it directly, outside the normal Part D benefit, so your plan does not have to opt in.
Cost$50/mo flat copay — the Part D deductible does NOT apply
WhoMedicare Part D members
Which drugs
ONLY three products qualify: Foundayo (all forms), Wegovy (both the injection and the tablets), and the Zepbound KwikPen. Zepbound single-dose VIALS and single-dose pens are NOT included — the ~$299/mo self-pay vials do not qualify. Ozempic and Mounjaro are NOT eligible either (they're diabetes drugs; ordinary Part D coverage for diabetes is a separate, existing path).
Who qualifies
Medicare Part D members — either a stand-alone Part D plan in Original Medicare, or a Medicare Advantage plan that includes drug coverage — who meet the clinical criteria. Your plan does not need to "participate": the Bridge operates outside Part D, through a CMS central processor.
The catch — read this
What to do
Confirm you have Part D drug coverage (stand-alone Part D, or Medicare Advantage with drugs).
You do not need your plan's permission — the Bridge operates outside the normal Part D benefit, run directly by CMS through a central processor. Plans don't opt in, and the pharmacy bills the Bridge, not your plan.
See your clinician to confirm you meet the clinical criteria and get the prescription written for a Bridge-eligible product — Foundayo, Wegovy (injection or tablets), or the Zepbound KwikPen (not Zepbound vials).